AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26892669 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicorder
Number of subjects: 80
Study 26892669 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 80
Study 26892942 — intervention group
Group type: EXPERIMENTAL
Intervention: DMDD group
Number of subjects: 71
Study 26892942 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar disorder group
Number of subjects: 71
Study 26892942 — intervention group
Group type: COMPARATOR
Intervention: Healthy youths
Number of subjects: 71
Study 26893034 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung diffusing capacity for nitric oxide (DLNO)
Number of subjects: 60
Study 26893034 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung diffusing capacity for carbon monoxide (DLCO)
Number of subjects: 60
Study 26893034 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusive conductance (DMCO)
Number of subjects: 60
Study 26893034 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary capillary volume (VC)
Number of subjects: 60
Study 26893034 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of DLNO
Number of subjects: 60
Study 26893034 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of DLCO
Number of subjects: 60
Study 26893128 — intervention group
Group type: EXPERIMENTAL
Intervention: Go! intervention (pedometer distribution, food labeling, persuasive messaging, integration of influential employees)
Number of subjects: 500
Study 26893128 — intervention group
Group type: EXPERIMENTAL
Intervention: Go! intervention
Number of subjects: 500
Study 26893128 — intervention group
Group type: COMPARATOR
Intervention: Control group (clinic employees)
Number of subjects: 500
Study 26893170 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral melatonin
Number of subjects: 12
Study 26893170 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg intravenous melatonin
Number of subjects: 12
Study 26893500 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 2830
Study 26893500 — intervention group
Group type: COMPARATOR
Intervention: Prior failure of a tumour necrosis factor α antagonist
Number of subjects: 2830
Study 26893500 — intervention group
Group type: COMPARATOR
Intervention: Narcotic analgesic use
Number of subjects: 2830
Study 26893500 — intervention group
Group type: COMPARATOR
Intervention: Younger age
Number of subjects: 2830
Study 26893500 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid use
Number of subjects: 2830
Study 26894920 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal transplantation
Number of subjects: 11
Study 26895374 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of parental warmth
Number of subjects: 44
Study 26895374 — intervention group
Group type: EXPERIMENTAL
Intervention: General parenting dimensions (including warmth)
Number of subjects: 44
Study 26895374 — intervention group
Group type: EXPERIMENTAL
Intervention: Program completion
Number of subjects: 44
Study 26895374 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean BMI change
Number of subjects: 44
Study 26895792 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean HbA1c increase by 1 percentage point
Number of subjects: 0
Study 26895792 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and mean HbA1c combined
Number of subjects: 0
Study 26895792 — intervention group
Group type: EXPERIMENTAL
Intervention: Final models including all significant risk factors
Number of subjects: 0
Study 26895876 — intervention group
Group type: EXPERIMENTAL
Intervention: Birthweight (BW) in grams
Number of subjects: 10652
Study 26895876 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age (GA) in days
Number of subjects: 10652
Study 26895885 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-Augmented Pump Use
Number of subjects: 0
Study 26895885 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 26895949 — intervention group
Group type: EXPERIMENTAL
Intervention: GH replacement therapy for 6 months in the GH Rx group, dosage titrated to achieve normal IGF-1 levels.
Number of subjects: 22
Study 26895949 — intervention group
Group type: COMPARATOR
Intervention: Non-GH replacement therapy in the non-GH Rx group.
Number of subjects: 22
Study 26895949 — intervention group
Group type: COMPARATOR
Intervention: GHD patients (22) vs healthy controls (44).
Number of subjects: 22
Study 26896024 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component care transitions programs
Number of subjects: 0
Study 26896024 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus groups
Number of subjects: 0
Study 26896024 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-methods approach
Number of subjects: 0
Study 26896370 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch
Number of subjects: 99
Study 26896466 — intervention group
Group type: EXPERIMENTAL
Intervention: Galectin-3
Number of subjects: 583
Study 26896684 — intervention group
Group type: EXPERIMENTAL
Intervention: Shanchol™ stored at 2-8°C (Group A)
Number of subjects: 580
Study 26896684 — intervention group
Group type: EXPERIMENTAL
Intervention: Shanchol™ stored at 25°C (Group B)
Number of subjects: 580
Study 26896684 — intervention group
Group type: EXPERIMENTAL
Intervention: Shanchol™ stored at 37°C (Group C)
Number of subjects: 580
Study 26896684 — intervention group
Group type: EXPERIMENTAL
Intervention: Shanchol™ stored at 42°C (Group D)
Number of subjects: 580
Study 26896684 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A-D)
Number of subjects: 580
Study 26896702 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial genomic classifier
Number of subjects: 222
Study 26896702 — intervention group
Group type: COMPARATOR
Intervention: Invasive procedures after inconclusive bronchoscopy
Number of subjects: 222
Study 26897304 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal filter (Rhinix)
Number of subjects: 1073
Study 26897675 — intervention group
Group type: EXPERIMENTAL
Intervention: High on-treatment platelet reactivity (HPR) defined as platelet reactivity >208 P2Y12 reaction unit
Number of subjects: 773
Study 26897675 — intervention group
Group type: EXPERIMENTAL
Intervention: High on-treatment platelet reactivity (HPR)
Number of subjects: 773
Study 26897675 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of angiographic calcium
Number of subjects: 773
Study 26897966 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic radiofrequency ablation (RFA)
Number of subjects: 12
Study 26898568 — intervention group
Group type: COMPARATOR
Intervention: DTG 50 mg q24h alone
Number of subjects: 16
Study 26898568 — intervention group
Group type: EXPERIMENTAL
Intervention: DTG 50 mg q24h + CBZ 300 mg q12h
Number of subjects: 16
Study 26898607 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400mg twice daily and erlotinib 150mg daily in 28-day cycles
Number of subjects: 46
Study 26899539 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/Ritonavir (ATV/r)
Number of subjects: 517
Study 26899665 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (Briviact)
Number of subjects: 0
Study 26900584 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired associative stimulation (PAS)
Number of subjects: 34
Study 26900584 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (age/gender-matched)
Number of subjects: 34
Study 26900584 — intervention group
Group type: EXPERIMENTAL
Intervention: NMDAR encephalitis patients
Number of subjects: 34
Study 26900584 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessments in six patients
Number of subjects: 34
Study 26900642 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin replacement (6–12 months)
Number of subjects: 60
Study 26900642 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-, gender-, race-, and ethnicity-matched)
Number of subjects: 60
Study 26900869 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/severe peri-implantitis
Number of subjects: 596
Study 26901037 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Intravenous Anaesthesia with Propofol (TIVA)
Number of subjects: 190
Study 26901037 — intervention group
Group type: COMPARATOR
Intervention: Inhalational Anaesthesia with Sevoflurane
Number of subjects: 190
Study 26901102 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga/Stretching (YS) with Protein-Pacing (PP) diet
Number of subjects: 27
Study 26901102 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Resistance (FR) training with Protein-Pacing (PP) diet
Number of subjects: 27
Study 26901102 — intervention group
Group type: COMPARATOR
Intervention: Protein-Pacing (PP) diet only
Number of subjects: 27
Study 26901163 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib treatment
Number of subjects: 3202
Study 26901163 — intervention group
Group type: EXPERIMENTAL
Intervention: Locoregional therapies before sorafenib
Number of subjects: 3202
Study 26901163 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib treatment duration
Number of subjects: 3202
Study 26901787 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyocardially injected autologous bone marrow-derived mesenchymal stromal cells (MSCs) (mean: 61.5×10(6) cells per patient) injected into 10-16 viable sites at the border of the LV scar via a NOGA-guided catheter.
Number of subjects: 10
Study 26901787 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyocardially injected autologous bone marrow-derived mesenchymal stromal cells (MSCs)
Number of subjects: 10
Study 26902643 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine consumption
Number of subjects: 200
Study 26902643 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear regression model including age and 9 SNPs in ESR1, OPRM1, and COMT
Number of subjects: 200
Study 26902643 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal model including 3 SNPs in ESR1, OPRM1, and COMT
Number of subjects: 200
Study 26902643 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between rs4680 in COMT and rs4986936 in ESR1
Number of subjects: 200
Study 26902643 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs rs677830 and rs540825 of OPRM1 and rs9340799 of ESR1
Number of subjects: 200
Study 26902761 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-663068 400 mg BID
Number of subjects: 244
Study 26902761 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-663068 600 mg BID
Number of subjects: 244
Study 26902761 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-663068 800 mg BID
Number of subjects: 244
Study 26902761 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-663068 600 mg QD
Number of subjects: 244
Study 26902761 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-663068 1200 mg QD
Number of subjects: 244
Study 26902828 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily
Number of subjects: 0
Study 26902828 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib (20-240 mg daily)
Number of subjects: 0
Study 26902828 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib (20 mg)
Number of subjects: 0
Study 26902828 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 0
Study 26903002 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion therapy
Number of subjects: 11986
Study 26903002 — intervention group
Group type: EXPERIMENTAL
Intervention: Early aspirin administration
Number of subjects: 11986
Study 26903002 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel administration
Number of subjects: 11986
Study 26903277 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of ceftriaxone injection followed by 6 days of 400 mg of cefixime per day
Number of subjects: 37
Study 26903305 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA) using an electrical current of 0.8 mAmp at frequencies from 5-100 kHz
Number of subjects: 63
Study 26903311 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat (20-60 mg) and epirubicin (75 mg/m² on day 5) given in 21-day cycles.
Number of subjects: 40
Study 26903311 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat (50 mg, MTD) and epirubicin (75 mg/m² on day 5) given in 21-day cycles.
Number of subjects: 40
Study 26903337 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation
Number of subjects: 3022
Study 26903337 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical recognition of ARDS
Number of subjects: 3022
Study 26903337 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume management
Number of subjects: 3022
Study 26903337 — intervention group
Group type: EXPERIMENTAL
Intervention: Plateau pressure measurement
Number of subjects: 3022
Study 26903337 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP) management
Number of subjects: 3022
Study 26903337 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 3022
Study 26903337 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital mortality rates
Number of subjects: 3022
Study 26903408 — intervention group
Group type: EXPERIMENTAL
Intervention: Water (1l/d)
Number of subjects: 173
Study 26903408 — intervention group
Group type: COMPARATOR
Intervention: Dairy (skim milk, whey, casein)
Number of subjects: 173
Study 26903522 — intervention group
Group type: EXPERIMENTAL
Intervention: All optic zone diffractive multifocal IOL
Number of subjects: 50
Study 26903522 — intervention group
Group type: COMPARATOR
Intervention: Monofocal IOL
Number of subjects: 50
Study 26903524 — intervention group
Group type: EXPERIMENTAL
Intervention: INTRACOR treatment (Technolas femtosecond laser)
Number of subjects: 25
Study 26903799 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP variability parameters (ASV, CV, VIM) monitored at ICU
Number of subjects: 44
Study 26903799 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP variability parameters (CV, VIM) monitored at ICU
Number of subjects: 44
Study 26903799 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory parameters (MIP, MEP, PEF)
Number of subjects: 44
Study 26904207 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator response (BDR)
Number of subjects: 129
Study 26904207 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant BDR
Number of subjects: 129
Study 26904207 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-significant BDR
Number of subjects: 129
Study 26904404 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP2215 (novel FLT3-inhibitor)
Number of subjects: 0
Study 26904570 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 30 mg/m(2)/week and paclitaxel 50 mg/m(2)/week for 5 weeks
Number of subjects: 81
Study 26904570 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 40 mg/m(2)/week for 5 weeks (control arm)
Number of subjects: 81
Study 26905333 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine system (LNG-IUS)
Number of subjects: 75
Study 26907184 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem (Empirical Therapy)
Number of subjects: 704
Study 26907184 — intervention group
Group type: COMPARATOR
Intervention: Other carbapenems (Empirical Therapy)
Number of subjects: 704
Study 26907184 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem (Targeted Therapy)
Number of subjects: 704
Study 26907184 — intervention group
Group type: COMPARATOR
Intervention: Other carbapenems (Targeted Therapy)
Number of subjects: 704
Study 26907630 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T-cell therapy
Number of subjects: 7
Study 26907745 — intervention group
Group type: EXPERIMENTAL
Intervention: CT esophagram
Number of subjects: 84
Study 26908063 — intervention group
Group type: EXPERIMENTAL
Intervention: poly(ADP-ribose) polymerase inhibitors
Number of subjects: 0
Study 26908089 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (psychotropic medication)
Number of subjects: 211
Study 26908089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 26908190 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 26908408 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial hemorrhage
Number of subjects: 30
Study 26908408 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial edema
Number of subjects: 30
Study 26908408 — intervention group
Group type: EXPERIMENTAL
Intervention: Infarct zone edema (T2, in ms)
Number of subjects: 30
Study 26908408 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular end-diastolic volume
Number of subjects: 30
Study 26908541 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-efficient practices in large HIV trials
Number of subjects: 0
Study 26908541 — intervention group
Group type: EXPERIMENTAL
Intervention: New approaches to clinical trial infrastructure and financial management
Number of subjects: 0
Study 26908541 — intervention group
Group type: EXPERIMENTAL
Intervention: Central monitoring and harmonized regulations
Number of subjects: 0
Study 26908748 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent oral sex partners (within the prior 3 months) among men
Number of subjects: 409
Study 26908748 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime vaginal sex partners among women
Number of subjects: 409
Study 26908748 — intervention group
Group type: COMPARATOR
Intervention: Oral HPV infection clearance
Number of subjects: 409
Study 26908756 — intervention group
Group type: EXPERIMENTAL
Intervention: FMP2.1/AS01 vaccine
Number of subjects: 15
Study 26908756 — intervention group
Group type: COMPARATOR
Intervention: Infectivity control
Number of subjects: 15
Study 26908786 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hIL-7 (20 µg/kg)
Number of subjects: 107
Study 26908804 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF on all samples
Number of subjects: 281
Study 26908804 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF on standard samples
Number of subjects: 281
Study 26908804 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF on alternative samples
Number of subjects: 281
Study 26908804 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF on nasopharyngeal aspirate and stool
Number of subjects: 281
Study 26908855 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 394
Study 26911200 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended CRT (54Gy and 6 cycles of 5FU-based chemotherapy)
Number of subjects: 111
Study 26911200 — intervention group
Group type: COMPARATOR
Intervention: Standard CRT (54Gy and 2 cycles of 5FU-based chemotherapy)
Number of subjects: 111
Study 26911310 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 53
Study 26911408 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus panitumumab (5-FU, 3,200 mg/m(2), 48-hour continuous intravenous infusion; leucovorin, 200 mg/m(2) i.v.; irinotecan, 125 mg/m(2); oxaliplatin, 85 mg/m(2) i.v.; panitumumab, 6 mg/kg i.v.)
Number of subjects: 15
Study 26911408 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus panitumumab
Number of subjects: 15
Study 26911477 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 0
Study 26911477 — intervention group
Group type: COMPARATOR
Intervention: Platinum-based chemotherapy and other tyrosine kinase inhibitors (erlotinib, afatinib)
Number of subjects: 0
Study 26911519 — intervention group
Group type: COMPARATOR
Intervention: Late spring/early summer period (April to June)
Number of subjects: 26
Study 26911519 — intervention group
Group type: COMPARATOR
Intervention: Treg numbers and function
Number of subjects: 26
Study 26911583 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP level assessment
Number of subjects: 182
Study 26911583 — intervention group
Group type: EXPERIMENTAL
Intervention: High (>2370 ng/L) and intermediate (806-2370 ng/L) NT-proBNP levels
Number of subjects: 182
Study 26911583 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate or high NT-proBNP level
Number of subjects: 182
Study 26911583 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate or high NT-proBNP level, presence of dementia, higher ASA classification
Number of subjects: 182
Study 26911589 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting MVPA guidelines
Number of subjects: 374
Study 26911589 — intervention group
Group type: EXPERIMENTAL
Intervention: MVPA and longer sleep duration
Number of subjects: 374
Study 26911589 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen time (ST) and healthy diet score
Number of subjects: 374
Study 26911589 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhealthy diet score
Number of subjects: 374
Study 26911589 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactions between lifestyle behaviours
Number of subjects: 374
Study 26911812 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninsured patients
Number of subjects: 279654
Study 26911812 — intervention group
Group type: COMPARATOR
Intervention: Factors associated with being uninsured (vs Medicaid-insured)
Number of subjects: 279654
Study 26911864 — intervention group
Group type: EXPERIMENTAL
Intervention: qPCR defined abnormal vaginal microbiota
Number of subjects: 130
Study 26911864 — intervention group
Group type: COMPARATOR
Intervention: Nugent-defined BV
Number of subjects: 130
Study 26911864 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall clinical pregnancy rate
Number of subjects: 130
Study 26911864 — intervention group
Group type: EXPERIMENTAL
Intervention: qPCR diagnostic approach
Number of subjects: 130
Study 26911864 — intervention group
Group type: EXPERIMENTAL
Intervention: Nugent intermediate flora
Number of subjects: 130
Study 26912134 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib 75 mg bd in combination with Cisplatin (25 mg/m²) and Gemcitabine (1000 mg/m²) administered on days 1 and 8 of a 21-day cycle.
Number of subjects: 13
Study 26912134 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and Gemcitabine (CisGem) standard of care.
Number of subjects: 13
Study 26912444 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 42
Study 26912444 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiandrogens
Number of subjects: 42
Study 26912444 — intervention group
Group type: EXPERIMENTAL
Intervention: (223)Ra-dichloride
Number of subjects: 42
Study 26912444 — intervention group
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Number of subjects: 42
Study 26912444 — intervention group
Group type: EXPERIMENTAL
Intervention: MATV response
Number of subjects: 42
Study 26912485 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills group training ('KONTAKT')
Number of subjects: 22